This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Andersen CL , Sikora MJ , Boisen MM , Ma T , Christie A , Tseng G , Park YS , Luthra S , Chandran U , Haluska P , Mantia-Smaldone G , Odunsi K , McLean K , Lee AV , Elishaev E , Edwards RP , Oesterreich S
Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens
Clin Cancer Res. 2017 Jul 15;23(14) :3802-3812
PMID: 28073843 PMCID: PMC5503796 URL: https://www.ncbi.nlm.nih.gov/pubmed/28073843
AbstractPURPOSE: High-grade serous ovarian cancer (HGSOC) is an aggressive disease with few available targeted therapies. Despite high expression of estrogen receptor-alpha in ~80% of HGSOC and some small but promising clinical trials of endocrine therapy, estrogen receptor-alpha has been understudied as a target in this disease. We sought to identify hormone-responsive, estrogen receptor-alpha-dependent HGSOC. EXPERIMENTAL DESIGN: We characterized endocrine response in HGSOC cells across culture conditions (2-D, 3-D, forced suspension) and in patient-derived xenograft (PDX) explants, assessing proliferation and gene expression. Estrogen-regulated transcriptome data were overlapped with public datasets to develop a comprehensive panel of estrogen receptor-alpha target genes. Expression of this panel and estrogen receptor-alpha H-score were assessed in HGSOC samples from patients who received endocrine therapy. Time on endocrine therapy was used as a surrogate for clinical response. RESULTS: Proliferation is estrogen receptor-alpha-regulated in HGSOC cells in vitro and in vivo, and is partly dependent on 3-D context. Transcriptomic studies identified genes shared by cell lines and PDX explants as estrogen receptor-alpha targets. The selective estrogen receptor-alpha down-regulator (SERD) fulvestrant is more effective than tamoxifen in blocking estrogen receptor-alpha action. Estrogen receptor-alpha H-score is predictive of efficacy of endocrine therapy, and this prediction is further improved by inclusion of target gene expression, particularly IGFBP3. CONCLUSIONS: Laboratory models corroborate intertumor heterogeneity of endocrine response in HGSOC but identify features associated with functional estrogen receptor-alpha and endocrine responsiveness. Assessing estrogen receptor-alpha function (e.g. IGFBP3 expression) in conjunction with H-score may help select patients who would benefit from endocrine therapy. Preclinical data suggest that SERDs might be more effective than tamoxifen.
NotesAndersen, Courtney L Sikora, Matthew J Boisen, Michelle M Ma, Tianzhou Christie, Alec Tseng, George Park, Yong Seok Luthra, Soumya Chandran, Uma Haluska, Paul Mantia-Smaldone, Gina Odunsi, Kunle McLean, Karen Lee, Adrian V Elishaev, Esther Edwards, Robert P Oesterreich, Steffi Journal Article United States Clin Cancer Res. 2017 Jan 10. pii: clincanres.1501.2016. doi: 10.1158/1078-0432.CCR-16-1501.